{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:45:16Z","timestamp":1781876716449,"version":"3.54.5"},"reference-count":132,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    The last decade represented a period of unprecedented interest in, and development of, traditional psychedelic substances for the treatment of a variety of neuropsychiatric disorders. While early clinical trials of classical psychedelics, several of the major ones being tryptamines, have demonstrated robust efficacy in patients with minimal adverse effects, many of these molecules have properties that may limit their broad utility in clinical practice or require more complex methods of delivery. The functional role and importance of a \u201cpsychedelic experience\u201d for therapeutic efficacy remain enigmatic. If the mechanism of action is reduced to mere 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    receptor activation, this raises the question if whether therapeutic efficacy is achievable without the psychedelic effects. Furthermore, as this class of molecules typically interacts with many other members of the serotonin receptor family, including the 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    and 5-HT\n                    <jats:sub>2C<\/jats:sub>\n                    receptor subtypes (receptors proven to be relevant to a multitude of neuropsychiatric disorders), as well as non-serotonergic receptors, the polypharmacological aspect of psychedelic tryptamines needs further scrutiny and understanding. In this perspective, the authors will review the limitations of the current classical non-conjugated tryptamines (excludes lysergic acid diethylamide, ibogaine, and similar molecules), highlighting approaches that have been explored to improve the molecules, as well as approaches to develop new generation psychedelic and \u201cnon-psychedelic\u201d compounds. Further, the authors will review the latest thoughts within the field on the pharmacology that could be underlying these potentially field changing therapies.\n                  <\/jats:p>","DOI":"10.1177\/02698811251368362","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:49:23Z","timestamp":1759582163000},"page":"1338-1350","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Modification of natural tryptamines for the treatment of neuropsychiatric diseases"],"prefix":"10.1177","volume":"39","author":[{"given":"Michael G.","family":"Palfreyman","sequence":"first","affiliation":[{"name":"Cybin IRL Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-7566","authenticated-orcid":false,"given":"Geoffrey B.","family":"Varty","sequence":"additional","affiliation":[{"name":"Cybin IRL Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stang","sequence":"additional","affiliation":[{"name":"Cybin IRL Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0040-7228","authenticated-orcid":false,"given":"Umed","family":"Boltaev","sequence":"additional","affiliation":[{"name":"Cybin IRL Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Avery","sequence":"additional","affiliation":[{"name":"Cybin IRL Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Nivorozhkin","sequence":"additional","affiliation":[{"name":"Cybin IRL Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2025.1527783"},{"key":"e_1_3_3_3_1","volume-title":"N,N-Dimethyltryptamine and Related Psychedelics and Uses Thereof, US11,866,408","author":"Alexander M","year":"2024","unstructured":"Alexander M, Duncton J, Clark S (2024) N,N-Dimethyltryptamine and Related Psychedelics and Uses Thereof, US11,866,408. United States Patent and Trademark Office."},{"key":"e_1_3_3_4_1","first-page":"157","article-title":"The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin","volume":"2022","author":"Araujo J","year":"2022","unstructured":"Araujo J, Higgins GA, De Lannoy IA, et al. (2022) The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Society for Neuroscience, vol 49 2022: 147.05. pp. 157-158","journal-title":"Society for Neuroscience"},{"key":"e_1_3_3_5_1","unstructured":"Arbe E (2023) A dose-finding and proof-of-concept study of the efficacy and safety of MSP-1014.OX in patients with major depressive disorder. Available at: file:\/\/\/E:\/Desktop\/Freelancer\/August\/19-08-2025\/pqd\/7593\/New%20folder\/study_record_ISRCTN31103960_2023-09-20.pdf (accessed 9 April 2025)."},{"key":"e_1_3_3_6_1","unstructured":"Atai Therapeutics I (2024) A study to assess the efficacy safety and tolerability of VLS-01 buccal film compared to placebo in patients with treatment resistant depression (ELUMINA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06524830 (accessed 9 April 2025)."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(82)90062-4"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(84)90404-0"},{"key":"e_1_3_3_9_1","unstructured":"Beckley Psytech Ltd. (2023) BPL-003 efficacy and safety in treatment resistant depression. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05870540 (accessed 9 April 2025)."},{"key":"e_1_3_3_10_1","volume-title":"Amorphous (A-Polymorphic) Psilocybin. WO2023237930","author":"Blumstock J","year":"2023","unstructured":"Blumstock J, Brown DR (2023) Amorphous (A-Polymorphic) Psilocybin. WO2023237930. World Intellectual Property Organization."},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2010.06.005"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.4c00058"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3008-z"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1333"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2016.04.016"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109398"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117371"},{"key":"e_1_3_3_21_1","volume-title":"Psilocybin and O-Acetylpsilocin, Salts and Solid State Forms Thereof, US11,851,452","author":"Clark S","year":"2023","unstructured":"Clark S (2023) Psilocybin and O-Acetylpsilocin, Salts and Solid State Forms Thereof, US11,851,452. United States Patent and Trademark Office."},{"key":"e_1_3_3_22_1","volume-title":"Psilocybin and O-Acetylpsilocin, Salts and Solid State Forms Thereof, US11,945,832","author":"Clark S","year":"2024","unstructured":"Clark S (2024) Psilocybin and O-Acetylpsilocin, Salts and Solid State Forms Thereof, US11,945,832. United States Patent and Trademark Office."},{"key":"e_1_3_3_23_1","volume-title":"Prodrugs and Derivatives of Psilocin and Uses Thereof, US20250011344","author":"Clark S","year":"2025","unstructured":"Clark S, Duncton M (2025) Prodrugs and Derivatives of Psilocin and Uses Thereof, US20250011344. United States Patent and Trademark Office."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyae057"},{"key":"e_1_3_3_25_1","unstructured":"Compass Pathways (2022a) Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: A proof-of-concept study. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05481736 (accessed 9 April 2025)."},{"key":"e_1_3_3_26_1","unstructured":"Compass Pathways (2022b) The safety and tolerability of COMP360 in participants with post-traumatic stress disorder. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05312151 (accessed 9 April 2025)."},{"key":"e_1_3_3_27_1","unstructured":"Compass Pathways (2023) Efficacy safety and tolerability of COMP360 in participants with TRD. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05624268 (accessed 9 April 2025)."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00597"},{"key":"e_1_3_3_29_1","unstructured":"Cybin IRL Ltd (2023) A study of a N N-dimethyltryptamine (DMT) analog (CYB004) in participants with generalized anxiety disorder (GAD). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06051721 (accessed 10 April 2025)."},{"key":"e_1_3_3_30_1","unstructured":"Cybin IRL Ltd (2024a) A study of a deuterated psilocin analog (CYB003) in humans with major depressive disorder (APPROACH). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06564818 (accessed 10 April 2025)."},{"key":"e_1_3_3_31_1","unstructured":"Cybin IRL Ltd (2024b) Safety tolerability pharmacokinetics (PK) pharmacodynamics (PD) and effects of intravenous (IV) and intramuscular (IM) dosing of SPL028 (deuterated DMT fumarate [a serotonergic psychedelic]) in healthy volunteers and participants with major depressive disorder (MDD). Available at: https:\/\/isrctn.com\/ISRCTN42293056 (accessed 10 April 2025)."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.21381"},{"key":"e_1_3_3_34_1","unstructured":"Diamond Therapeutics (2023) A 2-part phase 2A randomized double-blind trial to evaluate the safety tolerability and efficacy of psilocybin oral solution in adults with generalized anxiety disorder. Available at: https:\/\/health-products.canada.ca\/ctdb-bdec\/brand\/?submissionNo=270675 (accessed 10 April 2025)."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00703-8"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1246892"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73216-8"},{"key":"e_1_3_3_38_1","unstructured":"D\u2019Souza DC (2016) Psilocybin for the treatment of cluster headache. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02981173 (accessed 9 April 2025)."},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01404"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00970766"},{"key":"e_1_3_3_41_1","unstructured":"Eleusis Therapeutics (2022) ELE-101 safety & tolerability study in healthy participants and patients with depression. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05434156 (accessed 9 April 2025)."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-196710000-00005"},{"key":"e_1_3_3_43_1","unstructured":"Filament Health Corp. (2024a) PEX010-assisted therapy for opioid use disorder (OUD): A feasibility study. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06608459 (accessed 9 April 2025)."},{"key":"e_1_3_3_44_1","unstructured":"Filament Health Corp. (2024b) Psilocybin-assisted psychotherapy for alcohol use disorder (PAP-AUD). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05995769 (accessed 9 April 2025)."},{"key":"e_1_3_3_45_1","unstructured":"Filament Health Corp. (2025) PEX010-assisted therapy for stimulant use disorder: A safety feasibility and efficacy study (PATSUD). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06666010 (accessed 9 April 2025)."},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(24)26444-0"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874473708666150107121331"},{"key":"e_1_3_3_48_1","unstructured":"GH Research Ireland Ltd (2019) Clinical study of GH001 in depression. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04698603 (accessed 9 April 2025)."},{"key":"e_1_3_3_49_1","unstructured":"GH Research Ireland Ltd (2022) Safety and pharmacokinetics of GH002 in healthy volunteers. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05753956 (accessed 9 April 2025)."},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.2c00177"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.3c00139"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00367a008"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-023-00822-y"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7"},{"issue":"1","key":"e_1_3_3_56_1","article-title":"Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder","volume":"86","author":"Goodwin GM","year":"2025","unstructured":"Goodwin GM, Nowakowska A, Atli M, et al. (2025) Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder. Journal of Clinical Psychiatry 86(1): 24m15449.","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0457-5"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"e_1_3_3_59_1","volume-title":"Novel Psilocin Derivatives Having Prodrug Properties, WO2022038299","author":"Grill M","year":"2022","unstructured":"Grill M (2022) Novel Psilocin Derivatives Having Prodrug Properties, WO2022038299. World Intellectual Property Organization."},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199602000-00004"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57956-7"},{"key":"e_1_3_3_62_1","volume-title":"C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using, US11,945,778","author":"Hagel JM","year":"2024","unstructured":"Hagel JM, Matinkkhoo K, Facchini PJ (2024) C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using, US11,945,778. United States Patent and Trademark Office."},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3006-z"},{"key":"e_1_3_3_64_1","unstructured":"Hendricks P (2023) Exploratory study of low dose psilocybin. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05227742 (accessed 9 April 2025)."},{"issue":"17","key":"e_1_3_3_65_1","article-title":"Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave N","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, et al. (2021) Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proceedings of the National Academy of Sciences of the United States of America 118(17): E2022489118.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01097.x"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1305796"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2016.1170135"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa087"},{"key":"e_1_3_3_70_1","volume-title":"Prodrugs of Dimethyltryptamine and Derivatives Thereof, US20240287107","author":"Khan TA","year":"2024","unstructured":"Khan TA, Perni RB, Gibbs AC (2024) Prodrugs of Dimethyltryptamine and Derivatives Thereof, US20240287107. United States Patent and Trademark Office."},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00176"},{"key":"e_1_3_3_72_1","volume-title":"Co-Crystals or Salts Comprising Psilocin, WO2023168023","author":"Knight J","year":"2023","unstructured":"Knight J, Austin T (2023a) Co-Crystals or Salts Comprising Psilocin, WO2023168023. World Intellectual Property Organization."},{"key":"e_1_3_3_73_1","volume-title":"Co-Crystals or Salts Comprising Psilocybin, WO2023168022","author":"Knight J","year":"2023","unstructured":"Knight J, Austin T (2023b) Co-Crystals or Salts Comprising Psilocybin, WO2023168022. World Intellectual Property Organization."},{"key":"e_1_3_3_74_1","first-page":"157","article-title":"Phase I results for DLX-001, a novel neuroplastogen under development for the treatment of major depressive disorder. In:","author":"Koenig A","year":"2024","unstructured":"Koenig A, van der Aa L, Pelletier N, et al. (2024) Phase I results for DLX-001, a novel neuroplastogen under development for the treatment of major depressive disorder. In: Neuropsychopharmacology. American College of Neuropsychopharmacology, p. 157\u2013158.","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_3_75_1","article-title":"Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: A narrative review of preliminary evidence","volume":"46","author":"Koning E","year":"2024","unstructured":"Koning E, Brietzke E (2024) Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: A narrative review of preliminary evidence. Trends in Psychiatry and Psychotherapy 46: e20220597.","journal-title":"Trends in Psychiatry and Psychotherapy"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001454"},{"key":"e_1_3_3_77_1","first-page":"176","volume-title":"Neuropsychopharmacology","author":"Krempien S","year":"2024","unstructured":"Krempien S, Kelman A, Mahableswarkar A, et al. (2024) CYB003 Produces Robust and Enduring Antidepressant Effects in Patients With Major Depressive Disorder (MDD). In: Neuropsychopharmacology, vol 49. American College of Neuropsychopharmacology, pp. 176\u2013177."},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320950567"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-022-01177-4"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.3c00143"},{"key":"e_1_3_3_81_1","unstructured":"Lobe Sciences Ltd (2023) Evaluation of safety rate and extent of absorption of psilocin mucate (psilocin-1). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06035900 (accessed 9 April 2025)."},{"issue":"1","key":"e_1_3_3_82_1","article-title":"Modern psychedelic microdosing research on mental health: A systematic review","volume":"26","author":"Lo DF","year":"2024","unstructured":"Lo DF, Zia H, Rajkumar P, et al. (2024) Modern psychedelic microdosing research on mental health: A systematic review. The Primary Care Companion to CNS Disorders 26(1): 23r03581.","journal-title":"The Primary Care Companion to CNS Disorders"},{"key":"e_1_3_3_83_1","volume-title":"Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use, US10,947,257","author":"Londesbrough DJ","year":"2021","unstructured":"Londesbrough DJ, Brown C, Northen JS, et al. (2021a) Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use, US10,947,257. United States Patent and Trademark Office."},{"key":"e_1_3_3_84_1","volume-title":"Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use, US10,954,259","author":"Londesbrough DJ","year":"2021","unstructured":"Londesbrough DJ, Brown C, Northen JS, et al. (2021b) Preparation of Psilocybin, Different Polymorphic Forms, Intermediates, Formulations and Their Use, US10,954,259. United States Patent and Trademark Office."},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.022"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2000.10400456"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00421-7"},{"key":"e_1_3_3_88_1","unstructured":"Mindstate Design Labs (2024) Single ascending dose study of MSD-001 in healthy participants. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06702332 (accessed 9 April 2025)."},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-025-01923-4"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110"},{"key":"e_1_3_3_91_1","author":"Morphy JR","year":"2024","unstructured":"Morphy JR (2024) 3-(2-(Dimethylamino)Ethyl)-1h-Indol-4-yl Derivatives, WO2024156732. World Intellectual Property Organization.","journal-title":"3-(2-(Dimethylamino)Ethyl)-1h-Indol-4-yl Derivatives, WO2024156732"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2024.01.002"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2004.07.044"},{"key":"e_1_3_3_94_1","first-page":"1","article-title":"Chemistry and structure-activity relationships of psychedelics","volume":"36","author":"Nichols DE","year":"2018","unstructured":"Nichols DE (2018) Chemistry and structure-activity relationships of psychedelics. Current Topics in Behavioral Neurosciences 36: 1\u201343.","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00132"},{"key":"e_1_3_3_96_1","volume-title":"Formulations of Psilocybin, WO2022243285","author":"Nivorozhkin A","year":"2022","unstructured":"Nivorozhkin A, Palfreyman M, Avery K, et al. (2022) Formulations of Psilocybin, WO2022243285. World Intellectual Property Organization."},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2017.1310218"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2019.21.2\/dnutt"},{"key":"e_1_3_3_99_1","volume-title":"Ester Analogs of Psilocin, Processes for the Preparation Thereof, and Methods of Use, US20240158350","author":"O\u2019Meara J","year":"2024","unstructured":"O\u2019Meara J, Kaur H, Ali AM, et al. (2024) Ester Analogs of Psilocin, Processes for the Preparation Thereof, and Methods of Use, US20240158350. United States Patent and Trademark Office."},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718001356"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01808"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2024.02.192"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020835"},{"issue":"1","key":"e_1_3_3_105_1","first-page":"146","article-title":"Psychedelics and the human receptorome","volume":"5","author":"Ray T","year":"2010","unstructured":"Ray T (2010) Psychedelics and the human receptorome. PLoS One 5(1): 146\u2013162.","journal-title":"PLoS One"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2022.100515"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15587"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1133414"},{"key":"e_1_3_3_109_1","unstructured":"Reunion Neuroscience Inc (2024) RE104 safety and efficacy study in postpartum depression. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06342310 (accessed 9 April 2025)."},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241246857"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109166"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000219761.05466.43"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2021.06.008"},{"key":"e_1_3_3_115_1","volume-title":"TiHKAL (Tryptamines I Have Known And Loved): The Continuation","author":"Shulgin AT","year":"1997","unstructured":"Shulgin AT, Shulgin A (1997) TiHKAL (Tryptamines I Have Known And Loved): The Continuation. Transform Press."},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07624-5"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90159-6"},{"key":"e_1_3_3_118_1","volume-title":"Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders, US11,591,353","author":"Slassi A","year":"2023","unstructured":"Slassi A, Araujo J (2023) Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders, US11,591,353. United States Patent and Trademark Office."},{"key":"e_1_3_3_119_1","unstructured":"Small Pharma Ltd (2021) SPL026 (DMT fumarate) in healthy subjects and MDD patients. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04673383 (accessed 9 April 2025)."},{"key":"e_1_3_3_120_1","unstructured":"Small Pharma Ltd (2023) IM and IV SPL026 drug product in healthy participants. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05644093 (accessed 9 April 2025)."},{"key":"e_1_3_3_121_1","volume-title":"DMT: The Spirit Molecule","author":"Strassman R","year":"2011","unstructured":"Strassman R (2011) DMT: The Spirit Molecule. Tantor Audio."},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13666141210222409"},{"key":"e_1_3_3_123_1","unstructured":"Tryptamine Therapeutics (2022) Evaluation of psilocybin (TRP-8802) in the treatment of binge eating disorder. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05035927 (accessed 9 April 2025)."},{"key":"e_1_3_3_124_1","unstructured":"Usona Institute (2022) Pharmacokinetics safety and tolerability of intramuscular 5-MeO-DMT in healthy volunteers. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05698095 (accessed 9 April 2025)."},{"key":"e_1_3_3_125_1","unstructured":"Usona Institute (2024) Psilocybin for major depressive disorder (MDD) (uAspire). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06308653 (accessed 9 April 2025)."},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01450-8"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232808"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44016-1"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232807"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2022.096"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07403-2"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00194"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(81)90497-4"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251368362","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251368362","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251368362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:24Z","timestamp":1777507944000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251368362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":132,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/02698811251368362"],"URL":"https:\/\/doi.org\/10.1177\/02698811251368362","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]}}}